alendronate has been researched along with Sensitivity and Specificity in 42 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "While alendronate inhibits atherosclerosis experimentally, its effect on lower limb ischemia risk is unknown." | 3.80 | Alendronate and risk of lower limb ischemic vascular events: a population-based cohort study. ( Chang, HL; Chang, HT; Chen, CK; Chen, TJ; Chen, YC; Chou, HP; Huang, YC; Lee, MH; Shih, CC, 2014) |
| "Five years of alendronate therapy for those diagnosed with osteoporosis." | 3.75 | Using the osteoporosis self-assessment tool for referring older men for bone densitometry: a decision analysis. ( Charlson, ME; Hollenberg, JP; Ito, K, 2009) |
| "We developed a decision analytic Markov model to compare the effects of alendronate therapy, raloxifene therapy, and HRT on risks of hip fracture, coronary heart disease (CHD), breast cancer, and life expectancy." | 3.70 | Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. ( Col, NF; Eckman, MH; Goldberg, RJ; Orr, RK; Pauker, SG; Ross, EM; Wong, JB, 1999) |
| "Sensitivity and specificity were used to assess the accuracy of change from baseline at month 6 in the biochemical markers for predicting prevention of bone loss in the spine over 2 years." | 2.69 | Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. ( Christiansen, C; Clemmesen, B; Ravn, P, 1999) |
| "Alendronate is an important representative of bisphosphonates, strongly polar compounds that lack chromophores." | 1.38 | Trimethylsilyldiazomethane derivatization coupled with solid-phase extraction for the determination of alendronate in human plasma by LC-MS/MS. ( Chen, M; Chen, X; Liu, K; Zhong, D, 2012) |
| "Alendronate effects were detected at 3 months, and marked bone density increases were noted in juxta-cortical areas compared to inner trabecular areas." | 1.35 | Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. ( Imai, K; Matsumoto, T; Nakamura, K; Ohnishi, I; Yamamoto, S, 2009) |
| "Pamidronate was used as the internal standard." | 1.33 | High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans. ( Kwon, KI; Yun, MH, 2006) |
| "Instability-induced bone resorption therefore seems to be reduced by bisphosphonates, but higher doses are needed to obtain this effect than to reduce bone resorption associated with normal remodeling of untraumatized bone." | 1.31 | Reduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats. ( Aspenberg, P; Astrand, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (21.43) | 18.2507 |
| 2000's | 20 (47.62) | 29.6817 |
| 2010's | 12 (28.57) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, T | 1 |
| Wang, L | 1 |
| Li, Y | 1 |
| Chen, S | 1 |
| Wang, R | 1 |
| Chen, DDY | 1 |
| Reyes, C | 1 |
| Tebe, C | 1 |
| Martinez-Laguna, D | 1 |
| Ali, MS | 1 |
| Soria-Castro, A | 1 |
| Carbonell, C | 1 |
| Prieto-Alhambra, D | 1 |
| Moriwaki, K | 3 |
| Fukuda, H | 1 |
| Chen, CK | 1 |
| Chang, HT | 1 |
| Chou, HP | 1 |
| Lee, MH | 1 |
| Chen, YC | 1 |
| Huang, YC | 1 |
| Chen, TJ | 1 |
| Chang, HL | 1 |
| Shih, CC | 1 |
| Xie, B | 1 |
| Liu, A | 1 |
| Fang, X | 1 |
| Chen, Y | 1 |
| Zhong, H | 1 |
| Barrantes-González, M | 1 |
| Espona-Quer, M | 1 |
| Salas, E | 1 |
| Giménez-Arnau, AM | 1 |
| Yoshimura, M | 1 |
| Noto, S | 1 |
| Takiguchi, T | 1 |
| Mori, T | 1 |
| Crandall, CJ | 1 |
| Ganz, DA | 1 |
| Mouri, M | 1 |
| Hagino, H | 1 |
| Hardouin, J | 1 |
| Guénin, E | 1 |
| Malosse, C | 1 |
| Caron, M | 1 |
| Lecouvey, M | 1 |
| Imai, K | 1 |
| Ohnishi, I | 1 |
| Matsumoto, T | 1 |
| Yamamoto, S | 1 |
| Nakamura, K | 1 |
| Ito, K | 1 |
| Hollenberg, JP | 1 |
| Charlson, ME | 1 |
| Anastassopoulos, G | 1 |
| Panteliou, S | 1 |
| Christopoulou, G | 1 |
| Stavropoulou, A | 1 |
| Panagiotopoulos, E | 1 |
| Lyritis, G | 1 |
| Khaldi, L | 1 |
| Varakis, J | 1 |
| Karamanos, N | 1 |
| de Boer, T | 1 |
| Wieling, J | 1 |
| Chen, M | 1 |
| Liu, K | 1 |
| Zhong, D | 1 |
| Chen, X | 1 |
| Lippuner, K | 1 |
| Johansson, H | 1 |
| Borgström, F | 1 |
| Kanis, JA | 1 |
| Rizzoli, R | 1 |
| Thomson, AB | 1 |
| Appleman, S | 1 |
| Keelan, M | 1 |
| Wallace, JL | 1 |
| DeHart, RM | 1 |
| Gonzalez, EH | 1 |
| Pioletti, DP | 1 |
| Rakotomanana, LR | 1 |
| Fukunaga, M | 1 |
| Xue, Q | 1 |
| Li, H | 1 |
| Zou, X | 1 |
| Bünger, M | 1 |
| Egund, N | 1 |
| Lind, M | 1 |
| Christensen, FB | 1 |
| Bünger, C | 1 |
| Ettinger, B | 1 |
| Hillier, TA | 1 |
| Pressman, A | 1 |
| Che, M | 1 |
| Hanley, DA | 1 |
| Makras, P | 1 |
| Kaltsas, GA | 1 |
| Athanasoulis, T | 1 |
| Papadogias, D | 1 |
| Zografos, GN | 1 |
| Kontogeorgos, G | 1 |
| Borboli, N | 1 |
| Piaditis, G | 1 |
| Schousboe, JT | 1 |
| Nyman, JA | 1 |
| Kane, RL | 1 |
| Ensrud, KE | 1 |
| Yun, MH | 1 |
| Kwon, KI | 1 |
| Gołkowski, F | 1 |
| Barczyński, M | 1 |
| Buziak-Bereza, M | 1 |
| Huszno, B | 1 |
| Cichoń, S | 1 |
| Zhu, LS | 1 |
| Lapko, VN | 1 |
| Lee, JW | 1 |
| Basir, YJ | 1 |
| Kafonek, C | 1 |
| Olsen, R | 1 |
| Briscoe, C | 1 |
| Bonde, M | 1 |
| Garnero, P | 3 |
| Fledelius, C | 1 |
| Qvist, P | 1 |
| Delmas, PD | 3 |
| Christiansen, C | 3 |
| Ravn, P | 3 |
| Clemmesen, B | 1 |
| Rosner, AJ | 1 |
| Grima, DT | 1 |
| Torrance, GW | 1 |
| Bradley, C | 1 |
| Adachi, JD | 1 |
| Sebaldt, RJ | 1 |
| Willison, DJ | 1 |
| Darte, C | 1 |
| Col, NF | 1 |
| Pauker, SG | 1 |
| Goldberg, RJ | 1 |
| Eckman, MH | 1 |
| Orr, RK | 1 |
| Ross, EM | 1 |
| Wong, JB | 1 |
| Hosking, D | 1 |
| Thompson, D | 1 |
| Cizza, G | 1 |
| Wasnich, RD | 1 |
| McClung, M | 1 |
| Yates, AJ | 1 |
| Bjarnason, NH | 1 |
| Alexandersen, P | 1 |
| Møllgaard, A | 1 |
| Rodríguez Escolar, C | 1 |
| Fidalgo García, ML | 1 |
| Rubio Cebrián, S | 1 |
| Hardy, P | 1 |
| Dain, M | 1 |
| Kaufman, JM | 1 |
| Johnell, O | 1 |
| Abadie, E | 1 |
| Adami, S | 1 |
| Audran, M | 1 |
| Avouac, B | 1 |
| Sedrine, WB | 1 |
| Calvo, G | 1 |
| Devogelaer, JP | 1 |
| Fuchs, V | 1 |
| Kreutz, G | 1 |
| Nilsson, P | 1 |
| Pols, H | 1 |
| Ringe, J | 1 |
| Van Haelst, L | 1 |
| Reginster, JY | 1 |
| Srivastava, AK | 1 |
| Bhattacharyya, S | 1 |
| Castillo, G | 1 |
| Miyakoshi, N | 1 |
| Mohan, S | 1 |
| Baylink, DJ | 1 |
| Watts, NB | 1 |
| Jenkins, DK | 1 |
| Visor, JM | 1 |
| Casal, DC | 1 |
| Geusens, P | 1 |
| Ptácek, P | 1 |
| Klíma, J | 1 |
| Macek, J | 1 |
| Astrand, J | 1 |
| Aspenberg, P | 1 |
| Kline, WF | 1 |
| Matuszewski, BK | 1 |
| Bayne, WF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Changes in Bone Density, Radiographic Texture Analysis and Bone Turnover During Two Years of Antiresorptive Therapy for Postmenopausal Osteoporosis[NCT00145977] | 36 participants (Actual) | Interventional | 2001-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percent Change in femoral neck BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -4.21 |
| Control | 0.04 |
Percent Change in lumbar spine BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 5.28 |
| Control | -1.48 |
Percent Change in peripheral heel BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 1.02 |
| Control | -1.99 |
To derive a measure of variability and directionality in the first moment of the power spectrum (FMP) in the region of interest of the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals, and FMP is calculated for each segment. We use iFMP (integrated FMP) as a measure of overall special frequency of the radiographic pattern. FMP characterizes spatial frequency in the radiographic pattern and the underlying trabecular structure. This corresponds to the coarseness or fineness of the radiographic texture pattern. A high level of FMP indicates thin and closely spaced trabecular structure. Low FMP indicates widely spaced dark areas usually corresponding to a strong, thick trabecular structure. (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 0.09 |
| Control | 1.04 |
"Root Mean Square (RMS) is a measure of the variability in the radiographic texture pattern, the relative difference in the contrast between light and dark areas is expressed in a grayscale level. In practical terms, a bone image with a washed-out appearance due to loss of trabecular structure such as that seen in osteoporosis, will have a low value for RMS because there will be relatively little contrast between lighter and darker areas of the image. An image of a bone with strong trabecular structure will have a high RMS value because the contrast between the lighter and darker areas of the image will be greater.~To derive a measure of variability in the RMS in the region of interest of the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals, and RMS is calculated for each segment. We use sdRMS (standard deviation of the RMS across the segments) as a measure of the direction dependence (anisotropy) of the trabeculae in the bone image." (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 6.85 |
| Control | 1.08 |
"Root Mean Square (RMS) is a measure of the variability in the radiographic texture pattern, the relative difference in the contrast between light and dark areas is expressed in a grayscale level. In practical terms, a bone image with a washed-out appearance due to loss of trabecular structure such as that seen in osteoporosis, will have a low value for RMS because there will be relatively little contrast between lighter and darker areas of the image. An image of a bone with strong trabecular structure will have a high RMS value because the contrast between the lighter and darker areas of the image will be greater.~To derive a measure of variability in the RMS in the region of interest in the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals, and RMS is calculated for each segment. The iRMS (integrated RMS) roughly corresponds to RMS averaged across all 24 angular sectors" (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -3.70 |
| Control | -0.53 |
To derive a measure of variability and directionality in the first moment of the power spectrum (FMP) in the region of interest of the bone image, the power spectrum is divided into 24 angular sectors at 15 degree intervals and FMP is calculated for each segment. We use minFMP (minimum FMP) to represent the lowest value of FMP across the 24 angular sectors corresponding to the special frequency in the most washed-out direction. FMP characterizes spatial frequency in the radiographic pattern and the underlying trabecular structure. This corresponds to the coarseness or fineness of the radiographic texture pattern. A high level of FMP indicates thin and closely spaced trabecular structure. Low FMP indicates widely spaced dark areas usually corresponding to a strong, thick trabecular structure. (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -3.61 |
| Control | -0.18 |
The Percent Change in Radiographic Texture Analysis (RTA) Minkowski Fractal Dimension (MINK) from Baseline to Month 24 is a description of the similarity of texture of the images at different magnifications. The Minkowski fractal dimension is calculated from the slope of the least -square fitted line relating log volume and log magnification. (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -0.06 |
| Control | 0.12 |
The Percent Change in Radiographic Texture Analysis (RTA) spectral density coefficient beta (BETA) from Baseline to Month 24 is an analysis of spectral density vs. the spacial frequency on a log-log plot. BETA is the coefficient (slope) of this plot. Higher values of beta correspond to rougher (strong bone) and lower values to smoother, higher-frequency texture pattern (washed out bone). (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | 3.09 |
| Control | 6.53 |
Percent Change in total hip BMD from Baseline to Month 24 (NCT00145977)
Timeframe: Baseline to Month 24
| Intervention | Percent Change (Mean) |
|---|---|
| Alendronate | -3.68 |
| Control | -0.77 |
3 reviews available for alendronate and Sensitivity and Specificity
| Article | Year |
|---|---|
Osteoporosis: point-of-care testing.
Topics: Absorptiometry, Photon; Alendronate; Calcitonin; Female; Humans; Osteoporosis, Postmenopausal; Point | 2004 |
[Bone mass measurement and evaluation of therapeutical response].
Topics: Absorptiometry, Photon; Aging; Alendronate; Biomarkers; Bone Density; Calcium; Estrogen Replacement | 2004 |
Background for studies on the treatment of male osteoporosis: state of the art.
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Body Height; Body Weight; Bone Density; Fractures | 2000 |
6 trials available for alendronate and Sensitivity and Specificity
| Article | Year |
|---|---|
Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa.
Topics: Administration, Oral; Aged; Alendronate; Biomarkers; Biopsy, Needle; Cytokines; Dinoprostone; Dose-R | 2003 |
Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Alendronate; Area Under Curve; Biomarkers; Bone | 1999 |
A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Double-Blind Method; Female; Huma | 1999 |
Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study.
Topics: Alendronate; Biomarkers; Bone Density; Cohort Studies; Collagen; Collagen Type I; Dose-Response Rela | 1999 |
Bone densitometry: a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Analysis of Variance; Bone Resorption; Diphosphona | 1999 |
Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density | 2001 |
33 other studies available for alendronate and Sensitivity and Specificity
| Article | Year |
|---|---|
Quantification of the bisphosphonate alendronate using capillary electrophoresis mass spectrometry with dynamic pH barrage junction focusing.
Topics: Alendronate; Electrophoresis, Capillary; Hydrogen-Ion Concentration; Linear Models; Mass Spectrometr | 2021 |
One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Databases, Factual; Denosuma | 2017 |
Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
Topics: Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysi | 2019 |
Alendronate and risk of lower limb ischemic vascular events: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Amputation, Surgical; Bone Density Conservation Agents; Cohort | 2014 |
Rapid determination of alendronate to quality evaluation of tablets by high resolution ¹H NMR spectroscopy.
Topics: Alendronate; Bone Density Conservation Agents; Proton Magnetic Resonance Spectroscopy; Quality Contr | 2014 |
Bisphosphonate-induced cutaneous adverse events: the difficulty of assessing imputability through patch testing.
Topics: Aged; Alendronate; Case-Control Studies; Diphosphonates; Drug Eruptions; Female; Humans; Ibandronic | 2014 |
A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.
Topics: Absorptiometry, Photon; Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agen | 2017 |
Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-B | 2017 |
Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Diphosphonates; Drug Adm | 2017 |
Electrospray tandem mass spectrometry of alendronate analogues: fingerprints for characterization of new potential prodrugs.
Topics: Alendronate; Bone Density Conservation Agents; Molecular Structure; Nitrogen; Prodrugs; Sensitivity | 2008 |
Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method.
Topics: Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; | 2009 |
Using the osteoporosis self-assessment tool for referring older men for bone densitometry: a decision analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone and Bones; Cost-Benefit Analysis; Densitometry; Humans; M | 2009 |
Vibrational bone characteristics versus bone density for the assessment of osteoporosis in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density; Disease Models, Animal; Female; Fourier Analysis; Linear Models; | 2010 |
Incurred sample accuracy assessment: design of experiments based on standard addition.
Topics: Alendronate; Artifacts; Calibration; Chromatography, Liquid; Female; Guidelines as Topic; Humans; Ma | 2011 |
Trimethylsilyldiazomethane derivatization coupled with solid-phase extraction for the determination of alendronate in human plasma by LC-MS/MS.
Topics: Alendronate; Chromatography, High Pressure Liquid; Diazomethane; Humans; Sensitivity and Specificity | 2012 |
Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland.
Topics: Age Distribution; Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density Conservation Agents | 2012 |
Can the increase of bone mineral density following bisphosphonates treatments be explained by biomechanical considerations?
Topics: Alendronate; Biomechanical Phenomena; Bone Density; Bone Remodeling; Clinical Trials, Phase III as T | 2004 |
Healing properties of allograft from alendronate-treated animal in lumbar spine interbody cage fusion.
Topics: Alendronate; Analysis of Variance; Animals; Biopsy, Needle; Bone Transplantation; Disease Models, An | 2005 |
Simple computer model for calculating and reporting 5-year osteoporotic fracture risk in postmenopausal women.
Topics: Aged; Alendronate; Bone Density; Computer Simulation; Female; Fractures, Bone; Humans; Middle Aged; | 2005 |
Treatment with oral biphosphonates can increase the sensitivity of sestamibi radionuclide imaging in patients with primary hyperparathyroidism.
Topics: Adenoma; Aged; Alendronate; Calcium; Female; Humans; Hyperparathyroidism; Hyperplasia; Male; Middle | 2005 |
Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women.
Topics: Aged; Alendronate; Bone Density; Bone Diseases, Metabolic; Cost-Benefit Analysis; Female; Fractures, | 2005 |
High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans.
Topics: Alendronate; Bone Density Conservation Agents; Calibration; Chemistry Techniques, Analytical; Chemis | 2006 |
[New horizons for increased sensitivity of radionuclide imaging in primary hyperparathyroidism].
Topics: Adenoma; Adult; Alendronate; Female; Humans; Hyperparathyroidism, Primary; Image Enhancement; Middle | 2006 |
A general approach for the quantitative analysis of bisphosphonates in human serum and urine by high-performance liquid chromatography/tandem mass spectrometry.
Topics: Alendronate; Bone Density Conservation Agents; Chromatography, High Pressure Liquid; Diazomethane; E | 2006 |
Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Topics: Adult; Alendronate; Amino Acid Sequence; Antibodies; Biomarkers; Bone Resorption; Collagen; Collagen | 1997 |
Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis.
Topics: Aged; Alendronate; Calcium; Cost-Benefit Analysis; Drug Therapy, Combination; Estradiol; Estrogen Re | 1998 |
Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.
Topics: Alendronate; Bone Density; Breast Neoplasms; Coronary Disease; Decision Support Techniques; Estrogen | 1999 |
[A cost-effectiveness analysis of alendronate compared to placebo in the prevention of hip fracture].
Topics: Aged; Alendronate; Cost-Benefit Analysis; Decision Support Techniques; Female; Hip Fractures; Humans | 1999 |
Monitoring individual response to hormone replacement therapy with bone markers.
Topics: Alendronate; Bone Density; Drug Monitoring; Female; Hormone Replacement Therapy; Humans; Osteoporosi | 2000 |
Development and evaluation of C-telopeptide enzyme-linked immunoassay for measurement of bone resorption in mouse serum.
Topics: Alendronate; Amino Acid Sequence; Animals; Bone Resorption; Calcium; Collagen; Collagen Type I; Enzy | 2000 |
Determination of alendronate in human urine as 9-fluorenylmethyl derivative by high-performance liquid chromatography.
Topics: Alendronate; Chromatography, High Pressure Liquid; Fluorenes; Humans; Reference Standards; Reproduci | 2002 |
Reduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats.
Topics: Alendronate; Animals; Bone Plates; Bone Resorption; Clodronic Acid; Diphosphonates; Disease Models, | 2002 |
Determination of 4-amino-1-hydroxybutane-1,1-bisphosphonic acid in urine by automated pre-column derivatization with 2,3-naphthalene dicarboxyaldehyde and high-performance liquid chromatography with fluorescence detection.
Topics: Alendronate; Chromatography, High Pressure Liquid; Diphosphonates; Fluorescence; Humans; Hydrogen Pe | 1990 |